Brief: BioArctic AB Says EU Approves Leqembi (Lecanemab) For Treatment Of Early Alzheimer's Disease
15/04/2025 16:27
April 15 (Reuters) - Eisai Co Ltd 4523.T: BIOARCTIC AB - EU APPROVES LEQEMBI® (LECANEMAB) FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE Source text: ID:nWkr3hfLqX Further company coverage: 4523.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China